Examining the Impact of Immunotherapy in Bladder Cancer
Joaquim Bellmunt, MD, PhD, discusses the impact of immunotherapy compared to chemotherapy as treatment of patients with bladder cancer.
Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses the impact of immunotherapy compared to chemotherapy as a treatment for patients with bladder cancer.
Initially, experts thought immunotherapy would replace chemotherapy, but only a small percentage of patients with metastatic bladder cancer, for example, have shown benefit with immunotherapy. This leaves room for improvement, Bellmunt says.
Chemotherapy in combination with immunotherapy has shown improved outcomes in other cancers such as kidney or lung cancer, Bellmunt says. In the future, he expects combination therapy to beat monotherapy in frontline bladder cancer.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
